`Aflibercept (WHO 2006)
`758 SEQ ID 16
`959 SEQ ID 16
`
`MVSYWDTGVLLCALLSCLLLTGSSSGSDTGRPFVEMYSEITIPEIIHMTEGRELVIPCRVTS
`wr rt rr rr rr rr rr rt rrr ree SDTGRPFVEMYSETPEIITHMTEGRELVIPCRVTS
`MVSYWDTGVLLCALLSCLLLTGSSSGSDTGRPFVEMYSEIPEITHMTEGRELVIPCRVTS
`MVSYWDTGVLLCALLSCLLLTGSSSGSDTGRPFVEMYSEIPEITHMTEGRELVIPCRVTS
`
`SEQ ID 2 (338 & 069)
`Aflibercept (WHO 2006)
`758 SEQ ID 16
`959 SEQ ID 16
`
`PNITVTLKKFPLDTLIPDGKRIIWDSRKGFIISNATYKEIGLLTCEATVNGHLYKTNYLT
`PNITVTLKKFPLDTLIPDGKRIIWDSRKGFIISNATYKEITGLLTCEATVNGHLYKTNYLT
`PNITVTLKKFPLDTLIPDGKRIIWDSRKGFIISNATYKEIGLLTCEATVNGHLYKTNYLT
`PNITVTLKKFPLDTLIPDGKRIIWDSRKGFIISNATYKEIGLLTCEATVNGHLYKTNYLT
`
`SEQ ID 2 (338 & 069)
`Aflibercept (WHO 2006)
`758 SEQ ID 16
`959 SEQ ID 16
`
`HRQTNTIIDVVLSPSHGIELSVGEKLVLNCTARTELNVGIDFNWEYPSSKHQHKKLVNRD
`HRQTNTIIDVVLSPSHGIELSVGEKLVLNCTARTELNVGIDFNWEYPSSKHQHKKLVNRD
`HRQTNTIIDVVLSPSHGIELSVGEKLVLNCTARTELNVGIDFNWEYPSSKHQHKKLYVNRD
`HRQTNTITIDVVLSPSHGIELSVGEKLVLNCTARTELNVGIDFNWEYPSSKHQHKKLYNRD
`
`SEQ ID 2 (338 & 069)
`Aflibercept (WHO 2006)
`758 SEQ ID 16
`959 SEQ ID 16
`
`LKTQSGSEMKKFLSTLTIDGVTRSDQGLYTCAASSGLMTKKNSTFVRVHEKDKTHTCPPC
`LKTQSGSEMKKFLSTLTIDGVTRSDQGLYTCAASSGLMTKKNSTFVRVHEKDKTHTCPPC
`LKTQSGSEMKKFLSTLTIDGVTRSDQGLYTCAASSGLMTKKNSTFVRVHEKDKTHTCPPC
`LKTQSGSEMKKFLSTLTIDGVTRSDQGLYTCAASSGLMTKKNSTFVRVHEKDKTHTCPPC
`
`SEQ ID 2 (338 & 069)
`Aflibercept (WHO 2006)
`758 SEQ ID 16
`959 SEQ ID 16
`
`PAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT
`PAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVOVSHEDPEVKFNWYVDGVEVHNAKT
`PAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT
`PAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT
`
`SEQ ID 2 (338 & 069)
`Aflibercept (WHO 2006)
`758 SEQ ID 16
`959 SEQ ID 16
`
`KPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY
`KPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY
`KPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY
`KPREEQYNSTYRVVSVLTVLHQOWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY
`
`SEQ ID 2 (338 & 069)
`Aflibercept (WHO 2006)
`758 SEQ ID 16
`959 SEQ ID 16
`
`TLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSK
`TLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSK
`TLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSK
`TLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSK
`
`60
`34
`60
`60
`
`120
`94
`120
`120
`
`180
`154
`180
`180
`
`240
`214
`240
`240
`
`300
`274
`300
`300
`
`360
`334
`360
`360
`
`420
`394
`420
`420
`
`SEQ ID 2 (338 & 069)
`Aflibercept (WHO 2006)
`758 SEQ ID 16
`959 SEQ ID 16
`
`LTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
`LTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG-
`LTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
`LTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
`
`458
`431
`458
`458
`
`Mylan Exhibit 1122
`Mylan v. Regeneron, IPR2021-00881
`Page 1
`
`Mylan Exhibit 1122
`Mylan v. Regeneron, IPR2021-00881
`Page 1
`
`